On January 22, 2008, the Nordic Group was granted the exclusive marketing and distribution rights to Hyalobarrier® for a number of European countries by Fidia Advanced Biopolymers.
Hyalobarrier® gel is the highly advanced bio-technology specialty product used for the prevention of post-surgical adhesions in abdominopelvic surgery.
Adhesions are internal scars : strand-like fibrous tissue that forms abnormal bonds between two parts of the body. After abdominal or pelvic surgery, adhesions can lead to severe clinical complications, such as bowel obstruction, infertility, and chronic abdominal or pelvic pain. There is a significant unmet medical need for the prevention of adhesions and their potential complications.
Hyalobarrier® is composed of an aqueous gel of ACP200®, an original auto-cross-linked ester of hyaluronic acid, and the product is an highly effective barrier for protecting and separating tissues after abdominopelvic surgery. Given its physical characteristics, Hyalobarrier® perfectly adheres to the tissue surface and to the abdominal wall, and is easy to manipulate during laparotomic, laparoscopic and hysteroscopic procedures. The product completely degrades within 7 days by following the natural pathway of hyaluronic acid
The Nordic Group will commercialize Hyalobarrier® in France, United Kingdom, Ireland, the Benelux, Denmark, Sweden, Norway, Finland, Iceland, Czech & Slovak Republics, Poland, Bulgaria and in Germany, and intends to launch the product in the second half of 2008.